Published • loading... • Updated
Nicotinamide riboside fails to slow progression of early Parkinson’s disease
Summary by Medical Xpress
4 Articles
4 Articles
Nicotinamide riboside fails to slow progression of early Parkinson’s disease
A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA.
·Mona Vale, Australia
Read Full Article
NAD-boosting treatment shows no Parkinson's benefit in yearlong trial
A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA.
·Douglas, United Kingdom
Read Full Article
Norwegian study with 410 patients finds no clinical benefit of nicotinamide riboside after one year.
Nikotinamid Ribozide worsened the symptoms of Parkinson's early illness.
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
